Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2190 studies found for:    "Carcinoid tumor"
Show Display Options
Rank Status Study
1 Not yet recruiting A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Ramucirumab;   Drug: Somatostatin Analog
2 Withdrawn Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Condition: Malignant Carcinoid Tumor
Intervention: Drug: 90Y-SMT487
3 Completed
Has Results
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Condition: Carcinoid Tumors
Intervention: Drug: Pasireotide (SOM230)
4 Recruiting A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Condition: Carcinoid Tumors
Interventions: Drug: Lanreotide;   Drug: Placebo (for sunitinib);   Drug: Sunitinib
5 Active, not recruiting A Study of Axitinib in Advanced Carcinoid Tumors
Condition: Carcinoid Tumor
Intervention: Drug: Axitinib
6 Available Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy
Condition: Midgut Carcinoid Tumor
Intervention: Drug: 177Lu-DOTA0-Tyr3-Octreotate
7 Recruiting Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Condition: Carcinoid Tumor
Intervention: Drug: Ziv-aflibercept
8 Completed A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
Condition: Carcinoid Tumor
Intervention: Drug: Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
9 Active, not recruiting A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Conditions: Carcinoid Tumor of the Small Bowel;   Neuroendocrine Tumour
Interventions: Drug: Octreotide LAR;   Drug: 177Lu-DOTA0-Tyr3-Octreotate
10 Recruiting Natural History of Familial Carcinoid Tumor
Condition: Carcinoid
Intervention:
11 Completed
Has Results
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Conditions: Carcinoid Tumor;   Malignant Carcinoid Syndrome
Interventions: Drug: Octreotide;   Drug: Placebo;   Drug: Everolimus
12 Active, not recruiting Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Conditions: Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention: Drug: Cabozantinib
13 Unknown  Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
Intervention: Drug: RAD001 (everolimus, Afinitor®)
14 Recruiting SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor
Intervention:
15 No longer available Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: Gallium-68 DOTATOC
16 Unknown  Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors
Condition: Carcinoid Neuroendocrine Cancer
Intervention:
17 Recruiting 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Conditions: Neuroendocrine Tumors;   Carcinoid Tumors
Intervention: Device: 68Ga-DOTATOC PET
18 Completed Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Condition: Neuroendocrine Tumor
Intervention: Drug: Pazopanib
19 Completed EPO906 in Carcinoid and Other Neuroendocrine Tumors
Conditions: Carcinoid;   Neuroendocrine Tumors
Intervention: Drug: EPO906 epothilone B
20 Completed Combination Targeted Radiotherapy in Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Other: 131-I MIBG and 111-In pentetreotide;   Other: 131-I MIBG and In-111 DOTATATE

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.